Cannabis Poland SA
0.22
PLN
+0.00
(-1.79%)
ISIN
PLBLOCM00013
Return %
Stock
S&P 500
1Y
-5.21
14.20
3Y
-12.40
81.12
5Y
-87.12
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Warsaw Poland
- IPO Date
- Apr 9, 2013
- Website
- cannabispolandsa.com
- Similar Companies
- Business
- Cannabis Poland S.A. is a Poland-based healthcare and biotechnology company engaged in the sourcing, importation, registration, wholesale distribution, and retail commercialization of pharmaceutical-grade medical cannabis and consumer hemp-derived wellness products. The company operates through two core business segments: the Pharmaceutical Medical Cannabis (THC) Segment and the Consumer Cannabidiol (CBD) Segment. The company's product and service portfolio comprises pharmaceutical raw materials, including standardized medical cannabis dried flower (Cannabis flos) and pharmaceutical-grade cannabinoid extracts designated for prescription dispensing across retail pharmacies; licensed wholesale pharmaceutical import and supply chain operations, including wholesale trading of narcotic drugs and psychotropic substances, importation logistics, regulatory consulting, and trade-matchmaking services conducted via its pharmaceutical subsidiary THC Pharma S.A.; consumer wellness and nutritional products, including full-spectrum and broad-spectrum CBD oils, water-soluble hemp drops, dietary supplements, and topical cannabinoid-infused cosmetics for humans and animals; inhalation and delivery devices, including medical-grade inhalers, electronic dry-herb vaporizers, and associated consumption accessories; digital retail and distribution channels, encompassing e-commerce storefronts such as HempWish.pl and Vapem.eu; and specialized research and education initiatives, including the cannabinoid knowledge platform MMedu.eu and research programs focused on therapeutic cannabis applications. Founded in 2012 and headquartered in Warsaw, Poland, the company is publicly listed on the NewConnect alternative trading system of the Warsaw Stock Exchange under the ticker symbol CBD. In recent operational and strategic developments, Cannabis Poland S.A. has accelerated its transition into the pharmaceutical medical cannabis supply market by securing substantial import permits for metric-ton quantities of pharmaceutical raw materials through THC Pharma S.A.; entering into an exclusive distribution agreement for Cannabis flos 20% THC formulations in Poland; securing long-term supply agreements for registered medicinal cannabis valued at several million PLN; signing international import partnerships with licensed producers across Portugal, Switzerland, and Colombia; and executing a term sheet to acquire an equity stake in a European cannabis genetics and breeding company to bolster proprietary research and development capabilities.